SCHEMBL2616458

SCHEMBL2616458

CC(=O)c1ccccc1NCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.61
ALDH1A1 P00352 2/20 0.61
HPGD P15428 2/20 0.61
POLB P06746 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
PLK1 P53350 1/20 0.55
RXFP1 Q9HBX9 2/20 0.52
KDM4E B2RXH2 4/20 0.50
KDM6B O15054 1/20 0.50
KDM4A O75164 1/20 0.50
KDM4D Q6B0I6 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
CFD P00746 1/20 0.49
HTT P42858 1/20 0.48
ASPH Q12797 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2691864 0.85 HSD17B10 (0.81) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL27327995 0.85 HSD17B10 (0.65) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL12725538 0.84 HIF1A (0.53) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL464918 0.84 HPGD (0.63) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL2754257 0.84 HSD17B10 (0.63) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL30311518 0.84 HSD17B10 (0.63) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL28644608 0.83 ADRA1D (0.58) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL22854454 0.83 ALDH1A1 (0.68) HSD17B10ALDH1A1HPGDPOLBCTDSP1
SCHEMBL12608931 0.83 RXFP1 (0.54) HSD17B10ALDH1A1HPGDL3MBTL1RXFP1
SCHEMBL5707716 0.82 HSD17B10 (0.61) HSD17B10ALDH1A1HPGDPOLBCTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115947690-B Preparation method of indazole molecular building block and application of indazole molecular building block in drug synthesis 安徽医科大学 2025-04-08 CN disclosed
CN-114716438-B Benzo [7,8] indolizine [1,2-c ] quinoline skeleton derivative and synthetic method thereof 常州大学 2023-05-23 CN disclosed
CN-114716438-A Derivative with benzo [7,8] indolizine [1,2-c ] quinoline skeleton and synthetic method thereof 常州大学 2022-07-08 CN disclosed
US-20150080351-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. 2015-03-19 US disclosed
US-20130267492-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2013-10-10 US disclosed
US-8211896-B2 Aryl sulfonamides CHEMOCENTRYX, INC. (US) 2012-07-03 US disclosed
US-20120101097-A9 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-04-26 US disclosed
US-20120014997-A1 ARYL SULFONAMIDES UNGASHE SOLOMON (US) 2012-01-19 US disclosed
EP-2392328-A1 Compounds for modulating TRPV3 Function Hydra Biosciences, Inc. (US) 2011-12-07 EP disclosed
US-20110201610-A1 ARYL SULFONAMIDES UNGASHE SOLOMON 2011-08-18 US disclosed
US-7906655-B2 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2011-03-15 US disclosed
US-20110021523-A1 ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2011-01-27 US disclosed
CN-101012170-B N-arylation method in water solution UNIV SUN YAT SEN 2010-12-08 CN disclosed
US-20100068176-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-03-18 US disclosed
CN-101012170-A N-arylation method in water solution UNIV SUN YAT SEN (CN) 2007-08-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068176-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS HSD17B10 1305/4885ALDH1A1 1144/4885HPGD 1775/4885
US-20120014997-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 HSD17B10 2850/4885ALDH1A1 1655/4885HPGD 3897/4885
US-20110021523-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 HSD17B10 2850/4885ALDH1A1 1655/4885HPGD 3897/4885
US-20110201610-A1 ARYL SULFONAMIDES CCR2, CCL2, CX3CR1 HSD17B10 2344/4885ALDH1A1 1258/4885HPGD 1168/4885
US-20150080351-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 HSD17B10 2850/4885ALDH1A1 1655/4885HPGD 3897/4885
US-20120101097-A9 ARYL SULFONAMIDES CCR2, CCL2, CX3CR1 HSD17B10 2344/4885ALDH1A1 1258/4885HPGD 1168/4885
US-20130267492-A1 ARYL SULFONAMIDES CCR9, CCR1, CCR2 HSD17B10 2850/4885ALDH1A1 1655/4885HPGD 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.